iThera in the news

As the world leader in optoacoustic imaging, iThera Medical’s multispectral optoacoustic tomography (MSOT) imaging systems are used for both preclinical and clinical research. Recently, iThera Medical’s MSOT Acuity Echo imaging system achieved CE mark as a medical device. MSOT is based on the conversion of light energy into sound waves, also known as the photoacoustic effect. Through hundreds of studies, MSOT users from world-leading research centers have already demonstrated its scientific and clinical value in numerous application areas.

The new inVision TRIO offers tremendous flexibility for imaging disease processes. The key innovation is the addition of TUCT, which provides an accurate image of the speed of sound in tissue and its change with disease, e.g., in the context of cancer or fibrosis. Through this new development, the inVision TRIO delivers complementary information from three modalities: MSOT, reflection-mode ultrasound CT, and transmission-mode ultrasound CT. Coupled with unique features like a seamless 660-1,300 nm wavelength range and calibrated signal quantification, the inVision TRIO will allow researchers to drive their applications into previously unexplored areas.

Christian Wiest, CEO of iThera Medical, describes the motivation to develop the inVision TRIO system: “With the MSOT inVision on the market since 2012 and our focus in the past years on clinical translation, we felt it was time to update our preclinical system. The original MSOT inVision was the world’s first tomographic optoacoustic imaging system. We are excited that the inVision TRIO will now follow in these footsteps as the world’s first tri-modality optoacoustic imaging system, incorporating TUCT as a breakthrough innovation.”

To learn more about the new inVision TRIO imaging platform, see www.ithera-medical.com/products/preclinical-research/invision-trio/.